Manatt Health’s Post

#CMS recently announced the “maximum fair prices” for the first 10 drugs subject to the #Medicare drug negotiation program, which are predicted to save the government billions when they take effect. However, it remains to be seen how these prices will impact the Medicare program, as well as how Part D coverage and utilization of these products may change. A new Manatt Health infographic by Alexander Dworkowitz, Adam Finkelstein, Erin Estey Hertzog, Michael Kolber, Ross Margulies and Helen Pfister provides detailed information on the 10 selected drugs and their prices and offers a metric to understanding the Medicare drug negotiation program. View the full infographic here:

Only two days left to register for our #webinar on #Medicare drug pricing negotiations with Anna Kaltenboeck and Anne Tumlinson! Register now for an engaging session that will compare results of negotiations with other price benchmarks, examine effects on Part D and beneficiary affordability, and delve into implications of Medicare negotiation going forward. Register here: https://lnkd.in/d3jw4GHk #InflationReductionAct #HealthPolicy #Pharma #DrugPricing

Medicare is starting to flex its negotiation muscles, as allowed under recent changes in the law (Inflation Reduction Act). Drug supply chains are complex, and big pharma companies are excellent at "working the system" to maximize profits - so the end result of these negotiations on consumer pocketbooks? Time will tell. https://lnkd.in/gPxMweZ9

INFLATION REDUCTION ACT NEWS: Today is the big day -- CMS is sending its initial drug pricing offers to manufacturers of 10 drugs. To accompany the opening round of negotiations, HHS launched www.LowerDrugCosts.gov, a website touting the patient benefits of the Inflation Reduction Act. Negotiations are private unless a #pharma manufacturer discloses its offer. In the meantime, read our POV to learn what's ahead for the IRA and #drugpricing: #marketacess Entrée Health Archbow Consulting

DRUG PRICE NEGOTIATION NEWS: All #pharma manufacturers participating in the first round of Medicare #drugprice negotiations have responded with counteroffers, according to the agency. What's next: Final negotiated prices will be published by September 1 and take effect in 2026. In addition, roughly 289,000 rural Part D enrollees are projected to save $1,000 or more in 2025 thanks to the new caps on out-of-pocket costs and other drug related provisions as part of the #InflationReductionAct, according to a HHS fact sheet. #marketaccess #managedcare #healthcareaccess #ruralhealthcare

CMS released final negotiated prices for the first ten prescription drug products selected under the Inflation Reduction Act (IRA) this morning. Although the published prices establish a starting point for Medicare’s new ability to negotiate with manufacturers and provide some insight for future rounds of negotiation, several questions about the program and its long-term impact remain, including: - How do the negotiated prices compare to prices in other countries (a favorite topic among lawmakers)? - Which patients will actually benefit from the savings generated by Medicare negotiations? - How will PBMs and insurers respond to negotiated prices? - What safeguards, if any, will CMS implement to ensure that PBMs and insurers maintain beneficiary access to drugs selected for negotiation? Explore these questions and more with NAVLIN Daily’s analysis of the newly published negotiated drug prices: https://lnkd.in/enKr75bd #NAVLIN #NAVLINdata #pharmanews #EVERSANA #marketaccess #CMS #IRA #Medicare #negotiations #pricing

News Update: Medicare Drug Price Negotiations 💊 💉 The Department of Health and Human Services (HHS) and top drugmakers reached an agreement last Thursday, August 15 after months of negotiations. This resulted in discounts ranging from 38% to 79% on top drugs in the U.S. The list of drugs includes Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp/Novolog. The new pricing will become effective January 1, 2026. According to the Department of Health and Human Services (HHS), individuals with Medicare prescription drug coverage can anticipate a collective estimated savings of $1.5 BILLION in out-of-pocket costs in 2026. Employers! Stay up to date on this issue, as it may affect your creditable coverage status beginning in 2025. #StayCompliant #MedicarePartD

Canada’s new Target Zero initiative Designed to address the lag between when Health Canada approves a drug for use in Canada and when CADTH, a body responsible for drug reimbursement recommendations, makes a recommendation to public drug plans. By aiming for zero days between these two key steps, the initiative seeks to speed up patient access to new drugs.   Why does it Matter? Traditionally, there could be significant delays between regulatory approval and reimbursement recommendation, which affects patients' ability to access new medications. By reducing or eliminating these delays, patients can benefit from innovative treatments much sooner. #marketaccess #canada #hta

CMS releases draft guidance for second year of Medicare drug price negotiations; up to 15 additional Part D drugs will be selected for negotiation by 2/1/2025, with negotiated Maximum Fair Prices (MFPs) taking effect 1/1/2027. Single-source products potentially could be considered for negotiations if their initial FDA approved occurred before 2/1/2018 (for drugs) or 2/1/2014 (for biologicals). Please contact me if you have questions about the new draft guidance or would like to discuss how Fortrea can assist manufacturers with assessing the implications of Medicare drug price negotiations for their products. #fortrea #marketaccess #consulting #IRA #medicare #policy #reimbursement

Payers Eye Rebate Leverage, UM in Response to Medicare-Negotiated Drug Prices: Now that CMS has revealed the prices of the first 10 drugs subject to Medicare price negotiation, all eyes are on how Part D plans will cover those drugs on their formularies in 2026, when the new prices go into effect. To that end, a recent poll fro... Read More #marketaccess #lifesciences #pbm